Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. August 2020 22:07 ET | Quelle: Junshi Biosciences

TopAlliance Appoints Patricia Keegan, M.D., as Chief Medical Officer

ROCKVILLE, Md., Aug. 09, 2020 (GLOBE NEWSWIRE) -- TopAlliance Biosciences, a wholly own subsidiary of Shanghai Junshi Biosciences (HKEX: 1877; SSE: 688180) today announced the appointment of Dr....
12. Juli 2020 20:00 ET | Quelle: Junshi Biosciences

Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China

SHANGHAI, China, July 12, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
12. Juli 2020 08:20 ET | Quelle: Junshi Biosciences

Junshi Biosciences Announces Approval of “B” Marker Removal from Company’s Stock Name by HKEX

SHANGHAI, China, July 12, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
07. Juni 2020 11:30 ET | Quelle: Junshi Biosciences

Junshi Biosciences Announces Dosing of First Healthy Volunteer in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China

First healthy volunteer has been dosed in a Phase I study of JS016, the first SARS-CoV-2 neutralizing antibody to enter the clinical stage in ChinaJunshi and Lilly will co-develop JS016 globallyJS016...
01. Juni 2020 10:50 ET | Quelle: Junshi Biosciences

Junshi Biosciences and Merck Announce Collaboration to Explore Promising New COMBINATION Treatment for Head and Neck Cancer Patients in China

SHANGHAI, China, June 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEK: 1877), a China-based biopharmaceutical company specializing in discovery, development and commercialization of novel...
26. Mai 2020 10:10 ET | Quelle: Junshi Biosciences

Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies

CB6 demonstrated prophylactic and treatment effects in rhesus monkeys Clinical testing expected to begin in second quarter in collaboration with Eli Lilly and Company SHANGHAI, China, May 26, 2020...
07. Mai 2020 18:10 ET | Quelle: Junshi Biosciences

Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Locally Advanced or Metastatic Urothelial Carcinoma

SHANGHAI, China, May 07, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877) a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization...
04. Mai 2020 09:13 ET | Quelle: Junshi Biosciences

Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19

SHANGHAI and INDIANAPOLIS, May 04, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop...
30. April 2020 10:56 ET | Quelle: Junshi Biosciences

Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Advanced Nasopharyngeal Carcinoma

SHANGHAI, China, April 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
30. März 2020 21:29 ET | Quelle: Junshi Biosciences

Junshi Biosciences Announces Approval of Proposed A-Share Listing by the Listing Committee for the Shanghai Stock Exchange (SSE) STAR Market

SHANGHAI, China, March 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...

Vorherige Seite